Waleed Bolad, MD
Rheumatology · Orlando, FLNPI 1194907667
Payments from drug & device makers
Across 1,290 payments — averaging $89.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$33K
- GSK$26K
- Sanofi$25K
- AstraZeneca$9K
- Amgen$5K
- UCB, Inc.$4K
- plus $15K from 31 others
What the payments were for
- Consulting fees$5,8455%
- Speaking & faculty fees$82,12471%
- Grants$2400%
- Travel & lodging$5520%
- Food & beverage$26,46623%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 68 | $32,779 |
| GSK | 97 | $25,962 |
| Sanofi | 50 | $24,893 |
| AstraZeneca(2 entities) | 50 | $8,930 |
| Amgen(2 entities) | 198 | $4,565 |
| UCB, Inc. | 127 | $3,675 |
| AbbVie | 128 | $3,595 |
| Johnson & Johnson(3 entities) | 103 | $2,854 |
| Pfizer | 153 | $1,697 |
| Novartis | 81 | $1,575 |
| Aurinia Pharma U.S., Inc. | 37 | $890 |
| Lilly USA, LLC | 38 | $768 |
| ANI Pharmaceuticals, Inc. | 18 | $530 |
| Sobi, Inc | 27 | $498 |
| Genentech USA, Inc. | 18 | $303 |
| Mallinckrodt Enterprises LLC | 25 | $302 |
| E.r. Squibb & Sons, L.L.C. | 13 | $284 |
| Bristol Myers Squibb | 18 | $227 |
| Boehringer Ingelheim | 6 | $218 |
| Neurometrix Inc | 1 | $99 |
| Fresenius Kabi USA, LLC | 4 | $98 |
| Ferring Pharmaceuticals Inc. | 4 | $90 |
| Sandoz | 3 | $74 |
| Radius Health, Inc. | 4 | $63 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Antares Pharma, Inc. | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Cardinal Health Inc | 1 | $43 |
| Organon | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Invivyd Inc | 1 | $19 |
| Sebela Pharmaceuticals Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,390 in reported general payments places this provider in the 75th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 88 | $642,784 |
| Humira(Cf) PenAdalimumab | 67 | $486,670 |
| BenlystaBelimumab | 120 | $445,547 |
| RinvoqUpadacitinib | 41 | $272,066 |
| Xeljanz XrTofacitinib Citrate | 40 | $232,028 |
| KevzaraSarilumab | 49 | $204,071 |
| RemicadeInfliximab | 12 | $129,908 |
| SaphneloAnifrolumab-Fnia | 25 | $127,306 |
| Cimzia (2 Pack)Certolizumab Pegol | 21 | $126,963 |
| OrenciaAbatacept/Maltose | 20 | $104,333 |
| ProliaDenosumab | 32 | $55,730 |
| Mycophenolate Mofetil | 82 | $12,913 |
| Hydroxychloroquine Sulfate | 388 | $9,051 |
| Leflunomide | 120 | $5,216 |
| Pilocarpine Hcl | 61 | $5,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $25,962 | $445,547120 claims |
| AbbVieRinvoq | $3,595 | $272,06641 claims |
| SanofiKevzara | $24,893 | $204,07149 claims |
| Johnson & JohnsonRemicade | $2,854 | $129,90812 claims |
| AstraZenecaSaphnelo | $8,930 | $127,30625 claims |
| UCB, Inc.Cimzia (2 Pack) | $3,675 | $126,96321 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $284 | $104,33320 claims |
| AmgenProlia | $4,565 | $55,73032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Orlando
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.